Skip to main content
NASDAQ:AZYO

Aziyo Biologics Competitors

$11.00
+0.11 (+1.01 %)
(As of 05/14/2021 11:09 AM ET)
Add
Compare
Today's Range
$10.76
$11.00
50-Day Range
$9.51
$14.68
52-Week Range
$9.31
$18.20
Volume188 shs
Average Volume19,006 shs
Market Capitalization$112.49 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Aziyo Biologics (NASDAQ:AZYO) Vs. OYST, APTO, GRTS, JNCE, CDAK, and AVRO

Should you be buying AZYO stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Aziyo Biologics, including Oyster Point Pharma (OYST), Aptose Biosciences (APTO), Gritstone bio (GRTS), Jounce Therapeutics (JNCE), Codiak BioSciences (CDAK), and AVROBIO (AVRO).

Aziyo Biologics (NASDAQ:AZYO) and Oyster Point Pharma (NASDAQ:OYST) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aziyo Biologics and Oyster Point Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aziyo Biologics00403.00
Oyster Point Pharma00103.00

Aziyo Biologics currently has a consensus price target of $20.00, indicating a potential upside of 81.82%. Given Aziyo Biologics' higher probable upside, equities research analysts plainly believe Aziyo Biologics is more favorable than Oyster Point Pharma.

Insider and Institutional Ownership

70.2% of Oyster Point Pharma shares are held by institutional investors. 36.9% of Oyster Point Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Aziyo Biologics and Oyster Point Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aziyo BiologicsN/AN/AN/A
Oyster Point PharmaN/A-39.61%-37.68%

Earnings and Valuation

This table compares Aziyo Biologics and Oyster Point Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aziyo BiologicsN/AN/AN/AN/AN/A
Oyster Point PharmaN/AN/A$-45,710,000.00($9.97)-1.64

Summary

Aziyo Biologics beats Oyster Point Pharma on 4 of the 6 factors compared between the two stocks.

Aziyo Biologics (NASDAQ:AZYO) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aziyo Biologics and Aptose Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aziyo Biologics00403.00
Aptose Biosciences00803.00

Aziyo Biologics currently has a consensus price target of $20.00, indicating a potential upside of 81.82%. Aptose Biosciences has a consensus price target of $11.6250, indicating a potential upside of 139.69%. Given Aptose Biosciences' higher probable upside, analysts plainly believe Aptose Biosciences is more favorable than Aziyo Biologics.

Insider and Institutional Ownership

52.2% of Aptose Biosciences shares are held by institutional investors. 6.3% of Aptose Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Aziyo Biologics and Aptose Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aziyo BiologicsN/AN/AN/A
Aptose BiosciencesN/A-49.53%-46.65%

Earnings and Valuation

This table compares Aziyo Biologics and Aptose Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aziyo BiologicsN/AN/AN/AN/AN/A
Aptose BiosciencesN/AN/A$-26,280,000.00($0.52)-9.33

Summary

Aptose Biosciences beats Aziyo Biologics on 4 of the 6 factors compared between the two stocks.

Aziyo Biologics (NASDAQ:AZYO) and Gritstone bio (NASDAQ:GRTS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aziyo Biologics and Gritstone bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aziyo Biologics00403.00
Gritstone bio10202.33

Aziyo Biologics currently has a consensus price target of $20.00, indicating a potential upside of 81.82%. Gritstone bio has a consensus price target of $22.3333, indicating a potential upside of 157.59%. Given Gritstone bio's higher probable upside, analysts plainly believe Gritstone bio is more favorable than Aziyo Biologics.

Insider and Institutional Ownership

59.0% of Gritstone bio shares are held by institutional investors. 38.0% of Gritstone bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Aziyo Biologics and Gritstone bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aziyo BiologicsN/AN/AN/A
Gritstone bio-2,962.52%-101.31%-68.78%

Earnings and Valuation

This table compares Aziyo Biologics and Gritstone bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aziyo BiologicsN/AN/AN/AN/AN/A
Gritstone bio$4.36 million98.40$-94,430,000.00($2.81)-3.10

Aziyo Biologics has higher earnings, but lower revenue than Gritstone bio.

Summary

Aziyo Biologics beats Gritstone bio on 5 of the 9 factors compared between the two stocks.

Aziyo Biologics (NASDAQ:AZYO) and Jounce Therapeutics (NASDAQ:JNCE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aziyo Biologics and Jounce Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aziyo Biologics00403.00
Jounce Therapeutics11402.50

Aziyo Biologics currently has a consensus price target of $20.00, indicating a potential upside of 81.82%. Jounce Therapeutics has a consensus price target of $15.50, indicating a potential upside of 104.76%. Given Jounce Therapeutics' higher probable upside, analysts plainly believe Jounce Therapeutics is more favorable than Aziyo Biologics.

Insider and Institutional Ownership

60.5% of Jounce Therapeutics shares are held by institutional investors. 44.0% of Jounce Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Aziyo Biologics and Jounce Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aziyo BiologicsN/AN/AN/A
Jounce TherapeuticsN/A-72.91%-59.68%

Earnings and Valuation

This table compares Aziyo Biologics and Jounce Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aziyo BiologicsN/AN/AN/AN/AN/A
Jounce Therapeutics$147.87 million2.60$56.82 million$1.664.52

Jounce Therapeutics has higher revenue and earnings than Aziyo Biologics.

Summary

Jounce Therapeutics beats Aziyo Biologics on 4 of the 7 factors compared between the two stocks.

Aziyo Biologics (NASDAQ:AZYO) and Codiak BioSciences (NASDAQ:CDAK) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aziyo Biologics and Codiak BioSciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aziyo Biologics00403.00
Codiak BioSciences00303.00

Aziyo Biologics currently has a consensus price target of $20.00, indicating a potential upside of 81.82%. Codiak BioSciences has a consensus price target of $30.00, indicating a potential upside of 67.88%. Given Aziyo Biologics' higher probable upside, equities research analysts plainly believe Aziyo Biologics is more favorable than Codiak BioSciences.

Profitability

This table compares Aziyo Biologics and Codiak BioSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aziyo BiologicsN/AN/AN/A
Codiak BioSciencesN/AN/AN/A

Earnings and Valuation

This table compares Aziyo Biologics and Codiak BioSciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aziyo BiologicsN/AN/AN/AN/AN/A
Codiak BioSciencesN/AN/AN/AN/AN/A

Summary

Aziyo Biologics beats Codiak BioSciences on 2 of the 2 factors compared between the two stocks.

Aziyo Biologics (NASDAQ:AZYO) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Aziyo Biologics and AVROBIO, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aziyo Biologics00403.00
AVROBIO03602.67

Aziyo Biologics currently has a consensus price target of $20.00, indicating a potential upside of 81.82%. AVROBIO has a consensus price target of $24.2222, indicating a potential upside of 151.79%. Given AVROBIO's higher probable upside, analysts clearly believe AVROBIO is more favorable than Aziyo Biologics.

Insider & Institutional Ownership

86.7% of AVROBIO shares are owned by institutional investors. 4.8% of AVROBIO shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Aziyo Biologics and AVROBIO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aziyo BiologicsN/AN/AN/A
AVROBION/A-51.33%-47.65%

Valuation and Earnings

This table compares Aziyo Biologics and AVROBIO's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aziyo BiologicsN/AN/AN/AN/AN/A
AVROBION/AN/A$-72,960,000.00($2.66)-3.61

Summary

AVROBIO beats Aziyo Biologics on 4 of the 7 factors compared between the two stocks.


Aziyo Biologics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Oyster Point Pharma logo
OYST
Oyster Point Pharma
0.9$16.33+0.5%$422.14 millionN/A-4.71
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$4.85+4.7%$410.81 millionN/A-7.58
Gritstone bio logo
GRTS
Gritstone bio
1.6$8.72+6.5%$400.96 million$4.36 million-3.05Analyst Downgrade
Gap Up
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$7.51+3.7%$370.23 million$147.87 million-2.50
Codiak BioSciences logo
CDAK
Codiak BioSciences
2.0$17.87+6.8%$367.25 millionN/A0.00Gap Up
AVROBIO logo
AVRO
AVROBIO
1.9$9.61+8.5%$367.12 millionN/A-2.91Earnings Announcement
Analyst Report
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.4$8.27+1.8%$357.39 millionN/A0.00Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.8$3.68+1.6%$354.53 million$250,000.00-2.90Analyst Downgrade
Opthea logo
OPT
Opthea
1.5$8.03+3.5%$348.96 millionN/A0.00Gap Up
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.3$2.06+5.6%$336.80 million$8.15 million-1.64Upcoming Earnings
Gap Up
Surface Oncology logo
SURF
Surface Oncology
1.4$7.67+4.0%$319.64 million$15.36 million-11.62
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$8.57+0.9%$318.82 million$250,000.00-3.06Earnings Announcement
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.09+0.7%$316.69 million$2.91 million-2.12Analyst Report
News Coverage
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$12.04+6.0%$315.62 millionN/A0.00Earnings Announcement
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.7$9.44+7.3%$313.73 millionN/A0.00Analyst Report
News Coverage
Gap Up
Innate Pharma logo
IPHA
Innate Pharma
1.1$3.95+3.0%$312.01 million$96.12 million-11.62Gap Down
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.8$8.19+2.0%$272.63 millionN/A-3.37Analyst Report
Analyst Revision
Cabaletta Bio logo
CABA
Cabaletta Bio
1.6$9.42+6.8%$218.87 millionN/A-6.88
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.7$1.48+4.1%$198.51 million$4.13 million-3.29Earnings Announcement
Analyst Report
News Coverage
Gap Up
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$1.76+8.0%$196.47 million$29.35 million-2.05Earnings Announcement
Genfit logo
GNFT
Genfit
1.3$4.11+1.5%$188.14 million$45.88 million-2.09
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.5$4.48+4.2%$161.85 million$104.39 million-2.73Earnings Announcement
Analyst Report
Analyst Revision
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$6.46+4.0%$161.22 millionN/A-7.88Earnings Announcement
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$3.88+5.4%$156.90 million$2.45 million-1.82Upcoming Earnings
News Coverage
Gap Up
Gamida Cell logo
GMDA
Gamida Cell
1.4$6.60+4.5%$152.59 millionN/A-4.62Earnings Announcement
Analyst Revision
News Coverage
PolarityTE logo
PTE
PolarityTE
1.5$0.99+24.9%$150.00 million$5.65 million-0.59Earnings Announcement
Unusual Options Activity
News Coverage
Gap Down
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$4.76+6.9%$142.47 millionN/A-2.97Earnings Announcement
Analyst Revision
News Coverage
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$6.51+7.5%$140.75 millionN/A-1.66
INmune Bio logo
INMB
INmune Bio
1.5$10.16+8.6%$138.73 millionN/A-10.47Analyst Downgrade
Gap Up
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
2.0$6.27+1.6%$133.43 millionN/A0.00Earnings Announcement
Gap Up
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.3$10.00+2.0%$129.76 million$2.33 million0.00News Coverage
Gap Up
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$7.66+2.7%$129.51 millionN/A-2.39Gap Down
Axcella Health logo
AXLA
Axcella Health
1.6$3.41+2.3%$125.61 millionN/A-1.59Analyst Revision
News Coverage
Gap Up
Champions Oncology logo
CSBR
Champions Oncology
1.8$9.31+2.6%$121.45 million$32.12 million-71.62
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$3.41+5.6%$116.95 millionN/A-3.25
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$3.81+7.1%$112.36 million$20,000.000.00Upcoming Earnings
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.21+6.8%$112.14 millionN/A-1.52Analyst Revision
Dyadic International logo
DYAI
Dyadic International
1.3$3.85+0.3%$105.81 million$1.68 million-11.32Gap Down
Cidara Therapeutics logo
CDTX
Cidara Therapeutics
1.6$2.01+0.5%$97.55 million$20.92 million-1.16Earnings Announcement
News Coverage
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$9.05+4.1%$97.47 millionN/A0.00Analyst Upgrade
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$3.71+5.7%$96.07 million$23.05 million-1.65Analyst Downgrade
Analyst Revision
AIM ImmunoTech logo
AIM
AIM ImmunoTech
1.7$2.00+3.5%$92.30 million$140,000.000.00
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.7$6.04+3.8%$90.07 million$3 million-1.94
Seneca Biopharma logo
SNCA
Seneca Biopharma
0.5$4.60+14.1%$79.56 million$10,000.000.00Upcoming Earnings
Gap Up
Allena Pharmaceuticals logo
ALNA
Allena Pharmaceuticals
1.3$1.12+1.8%$65.68 millionN/A-0.89Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$3.63+0.3%$57.96 million$420,000.00-1.36Earnings Announcement
News Coverage
Brickell Biotech logo
BBI
Brickell Biotech
1.6$0.81+4.8%$56.89 million$7.92 million-0.34Earnings Announcement
News Coverage
BioCardia logo
BCDA
BioCardia
1.2$3.50+5.1%$55.75 million$710,000.00-1.80Earnings Announcement
News Coverage
Gap Up
Genetic Technologies logo
GENE
Genetic Technologies
0.4$3.68+2.2%$54.10 million$10,000.000.00
Idera Pharmaceuticals logo
IDRA
Idera Pharmaceuticals
1.8$1.01+0.0%$50.53 million$1.45 million-0.35
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.